Thalidomide

Generic Name: Thalidomide

Brand Names: Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₀N_₂O_₄

CAS Number: 50-35-1

Unique Ingredient Identifier: 4Z8R6ORS6L

Background: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.

Indication: Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions: Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma

Associated Therapies: -

Clinical Trials

The Effects of Thalidomide on Symptom Clusters

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: Thalidomide
Drug: Placebo

First Posted Date: 2006-09-21

Last Posted Date: 2013-02-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00379353

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-08-22

Last Posted Date: 2006-08-22

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 500

Registration Number: NCT00367185

Locations: 🇫🇷
Lille University Hospital, Lille, France

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-07-28

Last Posted Date: 2006-12-04

Lead Sponsor: University of Turin, Italy

Target Recruit Count: 30

Registration Number: NCT00358020

Locations: 🇮🇹
Divisione Di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy
🇮🇹
Divisione Di Ematologia E Trapianto Di Midollo Osseo, Azienda Ospedaliera Cervello, Palermo, Italy
🇮🇹
Cattedra E Divisione Di Ematologia, Università Tor Vergata, Ospedale S.Eugenio, Roma, Italy

and more 4 locations

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Lymphoma
Central Nervous System Tumor, Pediatric
Leukemia
Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide

First Posted Date: 2006-07-27

Last Posted Date: 2014-10-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00357500

Locations: 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 7 locations